Startups
CORAT Therapeutics GmbhCORAT Therapeutics GmbH develops an innovative therapeutic drug composed of a novel fully human neutralizing antibody against COVID-19, which very efficiently neutralizes SARS-CoV-2 and stop its spread within the human body. Our lead product, COR-101, decreased SARS-CoV-2 load in the lung by more than 99 % in the Hamster COVID-19 model, and induced recovery after 2 days, compared to 7 days untreated (more information). Our goal is to realize our vision of an immunotherapeutic remedy for acute COVID-19 as fast as possible. In contrast to any vaccine, such a drug is dedicated to treat and cure COVID-19 infected patients. The drug could additionally be used for passive immunization and immediate protection of people exposed to the virus such as people working in the healthcare system or people which have been in contact with infected patients. It could also be used impaired patients or risk groups (people suffering from underlying diseases having a high risk of severe COVID-19 infections.
Address
Inhoffenstraße 7, 38124 Brunswick, Germany
Commercial Register
GmbH
HRB 208500